1. Scrip

BMS/AbbVie Empliciti Leaps Ahead, Wins Fast FDA Nod

 
• By Donna Young

The FDA has been on a roll in granting early approvals of drugs to treat multiple myeloma – giving its nod to three new products in just the past couple of weeks well ahead of their Prescription Drug User Fee Act (PDUFA) goal dates, with Bristol-Myers Squibb Co.'s and AbbVie Inc.'s Empliciti (elotuzumab) being the latest.

The FDA has been on a roll in granting early approvals of drugs to treat multiple myeloma – giving its nod to three new products in just the past couple of weeks well ahead of their Prescription Drug User Fee Act (PDUFA) goal dates, with Bristol-Myers Squibb Co.'s and AbbVie Inc.'s Empliciti (elotuzumab) being the latest.

The FDA approved Empliciti in combination with Celgene Corp.'s Revlimid (lenalidomide) and dexamethasone in patients who have received one to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

More from Therapy Areas

Pfizer/Astellas’s Padcev Scores First Big Win In Bladder Cancer Study

 
• By Alaric DeArment

The drug, combined with Merck’s Keytruda, was successful among certain chemotherapy-ineligible MIBC patients, with another Phase III readout expected by March 2026.

Boehringer Scores First Approval For Targeted Oral Drug In HER2-Mutant NSCLC

 
• By Alaric DeArment

The US FDA approved Hernexeos for previously treated HER2-mutant NSCLC, making it the first oral option in a setting where drugs like AstraZeneca/Daiichi Sankyo’s Enhertu dominate.

Sjögren’s Success For Ianalumab Shores Up Novartis’s Pipeline-In-A-Product Plans

 
• By Alexandra Shimmings

Novartis has strengthened its argument that ianalumab, its BAFF-R inhibitor and ADCC-mediated B-cell depletor candidate, has PIP potential with successful topline results in two Phase III Sjögren’s syndrome trials, after recently dropping the product in hidradenitis suppurativa.